



Citi Pharma Limited

April 25, 2024

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.

Financial results for the 3rd quarter ended March 31, 2024

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on April 25, 2024 at Lahore have approved the financial statements for the 3rd Quarter ended on March 31, 2024 and recommended the following.

Cash Dividend	Nil
Bonus Shares	Nil
Right Shares	Nil
Any other entitlement/corporate action	Nil
Any other Price sensitive information	Nil

Financial Performance:

While reviewing the Company financial performance for the quarter ended, the Board appreciated the efforts of the management in the area of operation and posting the financial results.

Financial results of the company for the third quarter ended March 31, 2024 are enclosed.

Quarterly report of the Company for the quarter ended March 31, 2024 will be transmitted through PUCARS separately, within the specified time.

Yours Sincerely,

Rizwan Ahmad
Chief Executive Officer



Cc:
Executive Director/HOD, Offsite-II, Department
Supervision Division, Securities & Exchange Commission of Pakistan



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk



Citi Pharma Limited

CITI PHARMA LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE NINE MONTHS ENDED MARCH 31, 2024

	Quarter Ended		Nine Months Ended	
	March 31, 2024 (Un-audited)	March 31, 2023 (Un-audited)	March 31, 2024 (Un-audited)	March 31, 2023 (Un-audited)
	-----Rupees-----		-----Rupees-----	
Sales- Net	3,558,873,609	2,688,727,730	9,535,266,706	8,859,599,815
Cost of Sales	(3,087,343,974)	(2,338,312,529)	(8,192,103,683)	(7,593,756,702)
Gross Profit	471,529,635	350,415,201	1,343,163,023	1,265,843,113
Administrative Expenses	55,242,892	38,666,898	154,757,727	140,255,722
Selling Expenses	30,358,748	23,395,988	100,497,146	93,878,262
	(85,601,640)	(62,062,886)	(255,254,873)	(234,133,984)
Operating Profit	385,927,995	288,352,315	1,087,908,150	1,031,709,129
Financial (Cost) /Income	(43,826,747)	(156,023,397)	(200,800,962)	(277,626,004)
	342,101,248	132,328,917	887,107,188	754,083,124
Other Income/(Loss)	49,340,992	17,328,987	312,952,864	69,862,576
	391,442,239	149,657,905	1,200,060,051	823,945,701
Other Expenses	(26,569,358)	(10,476,053)	(82,062,737)	(52,846,538)
Profit Before Taxation	364,872,881	139,181,851	1,117,997,315	771,099,162
Taxation	(153,527,794)	(46,415,756)	(436,600,044)	(237,696,142)
Profit for the Period	211,345,087	92,766,096	681,397,271	533,403,021
Earnings per share (EPS) - Basic and Diluted	0.93	0.41	2.98	2.33



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory : +92. 49. 4510189, +92. 49. 4513392 | www.citipharma.com.pk